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Abstract
Small molecule drugs target many core metabolic enzymes in humans and pathogens, often mimicking endogenous
ligands. The effects may be therapeutic or toxic, but are frequently unexpected. A large-scale mapping of the intersection
between drugs and metabolism is needed to better guide drug discovery. To map the intersection between drugs and
metabolism, we have grouped drugs and metabolites by their associated targets and enzymes using ligand-based set
signatures created to quantify their degree of similarity in chemical space. The results reveal the chemical space that has
been explored for metabolic targets, where successful drugs have been found, and what novel territory remains. To aid
other researchers in their drug discovery efforts, we have created an online resource of interactive maps linking drugs to
metabolism. These maps predict the ‘‘effect space’’ comprising likely target enzymes for each of the 246 MDDR drug classes
in humans. The online resource also provides species-specific interactive drug-metabolism maps for each of the 385 model
organisms and pathogens in the BioCyc database collection. Chemical similarity links between drugs and metabolites
predict potential toxicity, suggest routes of metabolism, and reveal drug polypharmacology. The metabolic maps enable
interactive navigation of the vast biological data on potential metabolic drug targets and the drug chemistry currently
available to prosecute those targets. Thus, this work provides a large-scale approach to ligand-based prediction of drug
action in small molecule metabolism.
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Introduction
Drug developers have long mined small molecule metabolism for
new drug targets and chemical strategies for inhibition. The
approach leverages the ‘‘chemical similarity principle’’ [1] which
states that similar molecules likely have similar properties. Applied
to small molecule metabolism, this principle has motivated the
search for enzyme inhibitors chemically similar to their endogenous
substrates. The approach has yielded many successes, including
antimetabolites such as the folate derivatives used in cancer therapy
and the nucleoside analog pro-drugs used for antiviral therapy.
However, drug discovery efforts also frequently falter due to
unacceptable metabolic side-effect profiles or incomplete genomic
information for poorly characterized pathogens [2–4].
With the recent availability of large datasets of drugs and drug-
like molecules, computational profiling of small molecules has
been performed to create global maps of pharmacological activity.
This in turn provides a larger context for evaluation of metabolic
targets. For example, Paolini et al. [5] identified 727 human drug
targets associated with ligands exhibiting potency at concentra-
tions below 10 mM, thereby creating a polypharmacology
interaction network organized by the similarity between ligand
binding profiles. Keiser et al. [6] organized known drug targets
into biologically sensible clusters based solely upon the bond
topology of 65,000 biologically active ligands. The results revealed
new and unexpected pharmacological relationships, three of which
involved GPCRs and their predicted ligands that were subse-
quently confirmed in vitro. Cleves et al. [7] also rationalized several
known drug side effects and drug-drug interactions based upon
three-dimensional modeling of 979 approved drugs. However,
despite the clear rationale and past successes in applying ligand-
based approaches to drug discovery, global mapping between
PLoS Computational Biology | www.ploscompbiol.org 1 August 2009 | Volume 5 | Issue 8 | e1000474drugs and small molecule metabolism, the goal of this study, has
been hindered by both methodological challenges and incomplete
genomic information. The relatively recent availability of
metabolomes for numerous organisms allows a fresh look on a
large scale [8–13].
In this work, we link the chemistry of drugs to the chemistry of
small molecule metabolites to investigate the intersection between
small molecule metabolism and drugs. The Similarity Ensemble
Approach (SEA) [6] was used to link metabolic reactions and drug
classes by their chemical similarity, measured by comparing bond
topology patterns between sets of molecules. Two types of
molecule sets are used in this work. The first comprises drug-like
molecules known to act at a specific protein target, and the second
comprises the known substrates and products of an enzymatic
reaction. While this approach is complementary to target and
disease focused methods [5,14–23], neither protein structure nor
sequence information is used in the comparisons. Thus, these links
provide an orthogonal view of metabolism based only upon the
chemical similarity between existing drug classes and endogenous
metabolites.
To provide the results in the context of metabolism, drug
‘‘effect-space’’ maps were also created. For each of the 246 drug
classes investigated in this work, effect-space maps enable
visualization of the chemical similarities between drugs and
metabolites painted onto human metabolic pathways, allowing a
unique assessment of potential drug action in humans. In addition,
to aid target discovery in pathogens, 385 species-specific effect-
space maps were created to show the predicted effect-space of
currently marketed drugs, painted onto metabolic pathways
representing target reactions in model organisms and pathogens.
Examples of these maps are provided below and their applications
in predicting drug action, toxicity, and routes of metabolism are
discussed. To enable facile exploration of the drug-metabolite links
established by this analysis, interactive versions of both sets of
maps are available at http://sea.docking.org/metabolism.
Finally, using methicillin-resistant Staphylococcus aureus (MRSA), a
major pathogen causing both hospital- and community-acquired
infections that is resistant to at least one of the antibiotics most
commonly used for treatment [24–28] as an example, we show by
retrospective analysis the use of species-specific maps for discovery
and evaluation of drug targets. This also illustrates how additional
types of biological information can be incorporated to enhance the
value of these analyses.
Results
Drug-metabolite links reproduce known drug-target
interactions
To evaluate the chemical similarity between drug classes and
metabolic reactions, links between sets of metabolic ligands and
sets of drugs were generated according to SEA (Figure 1) [6]. The
similarity metric consists of a descriptor, represented by standard
two-dimensional topological fingerprints, and a similarity criteri-
on, the Tanimoto coefficient (Tc). Expectation (E) values were
calculated for each set pair by comparing the raw scores to a
background distribution generated using sets of randomly selected
molecules (see Methods for further details). To represent
metabolic ligand sets, the MetaCyc database, which includes
enzymes from more than 900 different organisms catalyzing over
6,000 reactions, was used [12]. The substrates and products of
each enzymatic reaction were combined to form a reaction set,
each of which was required to contain at least two unique
compounds (Datasets S1 and S2). Ubiquitous molecules called
common carriers, which frequently play critical roles in reaction
chemistry but do not distinguish the function of a specific enzyme,
were removed, leaving a total of 5,056 reactions involving 4,998
unique compounds. To represent drugs, a subset of 246 targets of
the MDL Drug Data Report (MDDR) collection, which annotates
ligands according to the targets they modulate, was used
(Datasets S3 and S4) [30]. These sets contain 65,241 unique
ligands with a median and mean of 124 and 289 ligands per target,
respectively. Overall, 246 drug versus 5,056 reaction set
comparisons involving 1.39610
9 pairwise comparisons were
made.
Although drugs and metabolites typically differ in their
physiochemical properties, significant and specific similarity links
nonetheless emerged. Using SEA at an expectation value cutoff of
E=1.0610
210, a previously reported cutoff for significance [6],
54% (132 of 246) of drug sets link to an average of 43.7
(median=10) or 0.9% of metabolic reactions. None of the
remaining 46% (114 of 246) of drug sets link to any metabolic
reaction sets. For instance, while the a-glucosidase drug set links to
the a-glucosidase reaction (E=1.00610
251), the thrombin
inhibitor drug set does not link significantly with any metabolic
reaction. The thrombin inhibitor drug set targets the serine
protease thrombin, which does not participate in small molecule
metabolism, but rather plays a role in the coagulation signaling
cascade. Likewise, 40% (2,044 of 5,056) of metabolic reactions hit
an average of 2.8 (median=2) or 1.1% of drug sets at expectation
value E=1.0610
210 or better. For instance, the metabolite set for
retinal dehydrogenase reaction set links, as expected, to the
retinoid drugs at E=3.056E
298, but the valine decarboxylase
reaction, which is not an MDDR drug target, does not link
significantly to any drug sets. These strikingly similar results
suggest both broad coverage (54% of drug sets and 40% of
metabolite sets) and specificity (single sets link to just 0.9% of
metabolite sets and 1.1% of drug sets, respectively). For full results,
see Dataset S5.
To determine the utility of the method for recovery of known
drug-target interactions, it was hypothesized that chemical
similarity between MetaCyc reaction sets and corresponding
MDDR drug sets could specifically recover the known drug-target
interactions. The 246 MDDR drug set targets include 62 enzymes
that could be mapped to MetaCyc via the Enzyme Commission
(EC) number [31] describing the overall reaction catalyzed [32].
The results show that all 62 reaction sets for these targets link to at
least one MDDR drug set. The majority of best hits (42 out of 62)
were found at expectation values of E=1.0610
210 or better
Author Summary
All humans, plants, and animals use enzymes to metab-
olize food for energy, build and maintain the body, and
get rid of toxins. Drugs used to clear infections or cure
cancer often target enzymes in bacteria or cancer cells, but
the drugs can interfere with the proper function of human
enzymes as well. Recent studies have mapped drugs to
enzymes and many other targets in humans and other
organisms, but have not focused on metabolism. In this
study, we present a new method to predict what enzymes
drugs might affect based on the chemical similarity
between classes of drugs and the natural chemicals used
by enzymes. We have applied the method to 246 known
drug classes and a collection of 385 organisms (including
65 National Institutes of Health Priority Pathogens) to
create maps of potential drug action in metabolism. We
also show how the predicted connections can be used to
find new ways to kill pathogens and to avoid uninten-
tionally interfering with human enzymes.
Drug Discovery in Small Molecule Metabolism
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225, 61%
(19 of 31) of best hits recover either the specific known target or
another enzyme in the same pathway. Examples of specific
compounds linked by this analysis are given in Figure 2 for a
selected group of these best-scoring hits.
Other links recovered off-pathway hits, which often reflect known
polypharmacology that is well-documented. For example, the
glycinamide ribonucleotide formyltransferase (GART) inhibitor
drug set hits both the GART reaction set (E=1.55610
282) and the
off-pathway but pharmacologically related antifolate target dihy-
drofolate reductase (DHFR) (E=1.02610
2134). Other off-pathway
hits reflect biological connections, or physical connections, between
targets. For example, the adenosine deaminase reaction set links to
the A1 adenosine receptor agonist drug set (E=7.69610
2159)
(Table 1) capturing the known interaction between A1 adenosine
receptors and adenosine deaminase on the cell surface of smooth
muscle cells [33]. Considering only the stringent case of exact
matches based on EC numbers, a Mann-Whitney rank-sum test
(also referred to as the U-test) shows that the expectation values for
links between reaction sets and drug sets of known drug target
enzymes were significantly better than the expectation values for
links to reaction sets of non-target enzymes, i.e., 62 known enzyme
targets were recovered in a background of 4,920 non-target ‘‘other’’
enzymes at a statistical significance of P=2.01610
26.
In addition to recapitulating many known drug-target interac-
tions, the links identified by these comparisons also suggest new
hypotheses about drug-target interactions. One such new
prediction involves the phospholipase A2 (PLA2) inhibitor drug
class. The substrates and products of PLA2 recapitulate its known
link to the PLA2 inhibitor drug set (E=9.82610
226), however, the
sterol esterase reaction returns an even better score against the
PLA2 inhibitor set (E=3.18610
244)( Table 1). Although this
predicted pharmacological relationship has, to our knowledge, not
been previously documented, the result is consistent with the
known biological relationship between PLA2 and sterol esterase.
Both enzymes are secreted by the pancreas and require
phosphatidylcholine hydrolysis to facilitate intestinal cholesterol
uptake [34]. Thus, this link suggests that therapeutic agents
directed against PLA2 may also inhibit sterol esterase, perhaps
even more strongly than their intended target.
Human drug ‘‘effect-space’’ maps detail interactions
between drug classes and enzyme targets
To present links between small molecule metabolites and drugs
in the context of their known (and potential) metabolic targets,
metabolic ‘‘effect-space’’ maps for currently marketed drugs were
generated for each of the 246 drug classes investigated in this
work. These maps enable visualization of the chemical similarities
between drugs and metabolites painted onto human metabolic
pathways, illustrating potential interactions between an individual
drug class and specific metabolic enzymes in humans. Examples
include the nucleoside reverse transcriptase, dihydrofolate reduc-
tase, and thymidylate synthase inhibitors which target pyrimidine
nucleotide metabolism and biosynthesis of the essential coenzyme
folate (Figure 3 and Table 2). Using the canonical human
metabolic pathways from HumanCyc [35], a subset of the BioCyc
[12] database collection, reactions in each metabolic network have
been colored according to their similarity to known drug classes
(Figure 3). While Table 1 presents only the top link for each of
62 enzyme targets in MetaCyc against the 246 MDDR drug
classes, the networks in Figure 3 detail all significant hits for
selected drug classes against the pyrimidine and folate pathways.
Interactive versions of these maps, one for each of the 246 drug
classes included in our analysis, are available online (see below).
Figure 1. Similarity Ensemble Approach (SEA). SEA compares
groups of ligands based upon bond topology. Example ligand sets
include the thymidylate synthase reaction set, composed of the
reaction substrates and products, and the nucleotide reverse transcrip-
tase inhibitor (NRTI) drug set, which includes known inhibitors of the
nucleoside reverse transcriptase enzyme. Fingerprints representing the
bond topology of each molecule are generated. Raw scores between
sets are calculated based upon Tanimoto coefficients between
fingerprints for all molecule pairs. Finally, the raw scores are compared
to a background distribution to determine the expectation value (E)
representing the chemical similarity between sets. See Methods for
further details.
doi:10.1371/journal.pcbi.1000474.g001
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known drugs often suggests novel drug-target interactions [5–
7,14]. Consistent with these observations, effect-space maps such
as those shown in Figure 3 can also be used to exploit chemical
similarities between drugs and metabolites to indicate potential
routes of drug metabolism and toxicity [3,11,36,37]. For example,
the nucleotide reverse transcriptase inhibitors (NRTIs) used in
HIV therapy are administered as pro-drugs. The effect-space map
reflects this route of NRTI metabolism leading to viral inhibition.
The top three hits yielded by the NRTI drug set queried against
Table 1. Metabolic enzyme targets and their best links to MDDR.
Enzyme Target
a EC# Best Hit MDDR Drug Set Best Hit E-value
Adenosine kinase 2.7.1.20 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 4.38E-288
Adenosylmethionine decarboxylase 4.1.1.50 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 2.71E-216
Thromboxane-A synthase 5.3.99.5 Prostaglandin 1.66E-204
Adenosylhomocysteinase 3.3.1.1 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 4.73E-203
Adenosine deaminase 3.5.4.4 Adenosine (A1) Agonist 7.69E-159
Thymidine kinase 2.7.1.21 Thymidine Kinase Inhibitor 3.19E-151
Dihydrofolate reductase 1.5.1.3 Glycinamide Ribonucleotide Formyltransferase Inhibitor 1.02E-134
Catechol O-methyltransferase 2.1.1.6 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 4.67E-127
Prostaglandin-endoperoxide synthase 1.14.99.1 Prostaglandin 8.57E-110
Purine-nucleoside phosphorylase 2.4.2.1 Adenosine (A1) Agonist 8.35E-105
Ribose-phosphate pyrophosphokinase 2.7.6.1 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 4.33E-91
Phosphoribosylglycinamide formyltransferase 2.1.2.2 Glycinamide Ribonucleotide Formyltransferase Inhibitor 1.55E-82
Phosphoribosylaminoimidazolecarboxamide formyltransferase 2.1.2.3 Glycinamide Ribonucleotide Formyltransferase Inhibitor 9.12E-80
39,59-cyclic-nucleotide phosphodiesterase 3.1.4.17 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 1.23E-77
Thymidylate synthase 2.1.1.45 Thymidylate Synthetase Inhibitor 2.54E-75
Steryl-sulfatase 3.1.6.2 Aromatase Inhibitor 4.90E-62
Guanylate cyclase 4.6.1.2 Purine Nucleoside Phosphorylase Inhibitor 2.68E-60
Cholestenone 5-alpha-reductase 1.3.1.22 Steroid (5alpha) Reductase Inhibitor 3.63E-60
Steroid 17-alpha-monooxygenase 1.14.99.9 Steroid (5alpha) Reductase Inhibitor 1.37E-58
RNA-directed DNA polymerase 2.7.7.49 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 1.06E-52
Alpha-glucosidase 3.2.1.20 Glucosidase (alpha) Inhibitor 1.00E-51
Farnesyl-diphosphate farnesyltransferase 2.5.1.21 Squalene Synthase Inhibitor 2.12E-46
Beta-galactosidase 3.2.1.23 Glucosidase (alpha) Inhibitor 4.04E-46
Sterol esterase 3.1.1.13 Phospholipase A2 Inhibitor 3.18E-44
Leukotriene-A4 hydrolase 3.3.2.6 Prostaglandin 5.16E-40
Squalene monooxygenase 1.14.99.7 Squalene Synthase Inhibitor 7.59E-40
Ribonucleoside-diphosphate reductase 1.17.4.1 S-Adenosyl-L-Homocysteine Hydrolase Inhibitor 2.47E-38
3-hydroxyanthranilate 3,4-dioxygenase 1.13.11.6 3-Hydroxyanthranilate Oxygenase Inhibitor 1.14E-33
Dihydroorotase 3.5.2.3 Dihydroorotase Inhibitor 2.25E-32
Nitric-oxide synthase 1.14.13.39 Nitric Oxide Synthase Inhibitor 8.86E-28
Phospholipase A2 3.1.1.4 Phospholipase A2 Inhibitor 9.82E-26
Diaminopimelate epimerase 5.1.1.7 Nitric Oxide Synthase Inhibitor 2.43E-24
Membrane dipeptidase 3.4.13.19 Nitric Oxide Synthase Inhibitor 2.81E-23
3-alpha(or 20-beta)-hydroxysteroid dehydrogenase 1.1.1.53 Aromatase Inhibitor 1.51E-22
Sterol O-acyltransferase 2.3.1.26 Adenosine (A2) Agonist 4.95E-22
Hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.34 Adenosine (A2) Agonist 4.95E-22
IMP dehydrogenase 1.1.1.205 Adenosine (A1) Agonist 8.98E-17
ATP-citrate (pro-S-)-lyase 4.1.3.8 Adenosine (A2) Agonist 1.83E-15
Glutamate–cysteine ligase 6.3.2.2 Nitric Oxide Synthase Inhibitor 2.71E-11
Dopamine-beta-monooxygenase 1.14.17.1 Adrenergic (beta1) Agonist 3.81E-11
Lanosterol synthase 5.4.99.7 Squalene Synthase Inhibitor 1.38E-10
Nucleoside-diphosphate kinase 2.7.4.6 P2T Purinoreceptor Antagonist 2.76E-10
aExact matches (the enzyme is the canonical target of the best MDDR hit) are shown in bold type, pathway matches (the enzyme shares the same pathway as the
canonical target of the best MDDR hit) are shown in italic type, and enzymes not in the same pathway as the canonical target are shown in regular type.
doi:10.1371/journal.pcbi.1000474.t001
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226), thymi-
dylate kinase (E=7.48610
228), and deoxythymidine diphosphate
kinase (E=1.54610
224)( Figure 3 reaction numbers 2, 3, and 4;
additional results in Table 2) – successively phosphorylate the
NRTI pro-drugs into the pharmacologically active NRTI
triphosphates [38,39]. The viral reverse transcriptase enzyme
then incorporates the fully phosphorylated NRTIs into the
growing DNA strand, thereby terminating transcription of the
viral DNA. In this example, considerable toxicity mitigates the
therapeutic value of inhibiting viral DNA transcription since the
phosphorylated NRTIs directly inhibit human nucleotide kinases
and mitochondrial DNA pol-c. They also may be incorporated by
pol-c into the growing human mitochondrial DNA strand, and
once incorporated are inefficiently excised by DNA pol-c
exonuclease [40]. Thus, the effect-space map illustrates both the
route of metabolism and a mechanism of toxicity for NRTIs in
humans.
Drug effect-space maps also offer a broad glimpse of potential
human metabolic interactions predicting new ‘‘polypharmacol-
ogy’’. From the ligand perspective, ‘‘drug polypharmacology’’
refers to a single drug or drug class that hits multiple targets. For
example, dihydrofolate reductase (DHFR, reaction number 7 in
Figure 3) uses NADPH to reduce 7,8-dihydrofolate to tetrahy-
drofolate. Antifolate drugs inhibit DHFR, and, as expected, the
DHFR drug set recovers the DHFR reaction substrates and
products as the top similarity hit in human metabolism
(E=1.46610
282)( Figure 3, Table 2, Figure 4). However, at
least 20 other reactions also use folate coenzymes in human
metabolism [41–43]. Accordingly, SEA finds additional links
between the DHFR drug set and established antifolate targets
outside the pyrimidine and folate biosynthesis pathways such as
serine hydroxymethyltransferase (SHMT, E=2.68610
244), phos-
phoribosyl-aminoimidazole-carboxamide formyltransferase (AI-
CAR transformylase, E=2.21610
239), and phosphoribosyl-glyci-
namide formyltransferase (GART, E=2.21610
239)( Table 2).
The effect-space maps in Figure 3 illustrate the results from
Table 2 and Figure 4 in a single view, illustrating drug
polypharmacology with respect to critical metabolic pathways.
Alternatively, from the target perspective, ‘‘target polypharma-
cology’’ may refer to a single target being modulated by multiple
classes of drugs. For instance, thymidylate synthase (TS) is another
classic antifolate target that uses a folate coenzyme to methylate
deoxyuridine phosphate, generating deoxythymidine phosphate
[44–47]. As expected, the TS reaction links to known antifolate
drug classes such as GART inhibitors (E=4.76610
273) and
DHFR inhibitors (E=1.91610
248)( Table 3 and Figure 4).
However, TS is also effectively inhibited by uracil analogs such as
fluoropropynyl deoxyuridine, which is not a folate, but rather a
pyrimidine analog. Accordingly, the TS reaction also links to
reverse transcriptase inhibitors, which include fluoropropynyl
Figure 2. Selected best hits between MetaCyc reaction sets and MDDR drug sets.
doi:10.1371/journal.pcbi.1000474.g002
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midine (AZT) (E=5.68610
211)( Figure 4). The target polyphar-
macology of the thymidylate synthase enzyme is mirrored by the
drug polypharmacology of the thymidylate synthase inhibitors. The
TS inhibitors link not only to the reactions of deoxyribonucleotide
biosynthesis including thymidylate synthase (E=2.54610
275), but
also the GART (E=1.50610
260) and DHFR (E=1.96610
2123)
reactions (Figure 3 and Table 2). Thus, SEA recapitulates the
known polypharmacology of TS. Effect-space maps illustrate and
clarify these pharmacological relationships.
Species-specific effect-space maps for pathogens and
model organisms
The great diversity of metabolic strategies, pathways, and
enzymes present in humans, model organisms, and pathogenic
species presents both opportunities and significant barriers to drug
discovery. To address these issues, species-specific effect-space
maps were created for each of 385 organisms from the BioCyc
Database Collection. Target reactions existing in common and
differentially between each of these species and humans are shown
in these metabolic maps. As with the human effect-space maps,
this set of maps is available in interactive form online. To show
how these maps may be used to provide a context for drug
discovery, MRSA is used as an example (Figure 5). The global
view of drugs and metabolism provided by this species-specific
map illustrates some of the daunting challenges to the selection of
tractable metabolic drug targets in this organism.
As described for Figure 3, each node in the MRSA network in
Figure 5 represents one reaction set, the substrates and products
of a single metabolic reaction. Edges connect the reactions
according to canonical BioCyc MRSA pathways. Each reaction in
the network has been colored according the expectation value of
the best link between the reaction set and any of the 246 MDDR
drug sets. Lighter colored nodes have higher expectation values
indicating less drug-like reaction sets, while darker colored nodes
indicate more drug-like reaction sets. To provide therapeutic
context, reactions that are also present in human metabolism have
been faded, indicating that drug sets targeting these enzymes in
MRSA may have the undesirable potential to inhibit the human
enzymes as well. As with the other organisms represented in our
online maps, most reactions in the MRSA subset have little
chemical similarity to any MDDR drug set. Although 74% of the
469 MRSA metabolic reactions have measurable similarity to at
least one MDDR drug set, only 36% of these links had expectation
values of E=1.0610
210 or better. Several complete pathways of
diverse chemical classes, including shikimic acid, phospholipid,
peptidoglycan, teichoic acid, and molybdenum cofactor biosyn-
thesis, lack links to any drug set at all. Only 18 of the 469 MRSA
metabolic reactions are already known to be drug targets in
MDDR. Fourteen of these are represented in Figure 5 (as
diamonds), but all 18 of these also appear in humans. Enzymes
that catalyze these reactions in humans would likely be vulnerable
to inhibitors developed against these MRSA targets, putting those
drugs at risk for toxicity.
Figure 6 illustrates how additional information can be used to
further filter potential metabolic targets by painting additional
biological or genomic data onto a species-specific map. Since
successful modulation of a target may not alone be sufficient to kill
a pathogen due to the presence of redundant pathways for the
formation of critical metabolites, integration of such additional
information into a metabolic map may provide added value in
addressing the multi-dimensional challenges of drug discovery.
Flux balance analysis of metabolic networks was used by several of
the authors of this work to identify essential enzymes and
Figure 3. Effect-space map showing chemical similarity be-
tween specific drug classes and metabolites in human folate
and pyrimidine biosynthesis. Each node represents one reaction set
– the substrates and products of a single human metabolic reaction.
Edges connect the reactions in the canonical pathway as annotated in
HumanCyc [35]. As given in the color key, each reaction is colored
according to the expectation value indicating the strength of similarity
between that target reaction set and the respective MDDR drug set.
Diamond shaped nodes indicate reactions catalyzed by enzymes
annotated as known drug targets in the MDDR; circles indicate
reactions catalyzed by enzymes not annotated as targets. Reaction
key: 1. Deoxyuridine kinase 2. Thymidine kinase 3. Thymidylate kinase 4.
Deoxythymidine diphosphate kinase 5. Thymidylate synthase (TS) 6.
Methylene tetrahydrofolate reductase 7. Dihydrofolate reductase
(DHFR) 8. Deoxyuridine diphosphate kinase 9. Deoxyuridine triphos-
phate diphosphatase.
doi:10.1371/journal.pcbi.1000474.g003
Drug Discovery in Small Molecule Metabolism
PLoS Computational Biology | www.ploscompbiol.org 6 August 2009 | Volume 5 | Issue 8 | e1000474metabolites required for the formation of all necessary biomass
components for 13 strains of Staphylococcus aureus ¸ including the
methicillin-resistant N315 strain (MRSA) [48]. Using these results,
39 essential reactions and 19 synthetic lethal reaction pairs could
be mapped to our dataset (Figure 6), highlighting those reactions
for which inhibition is most likely to result in the death of the
organism. Several of these reactions have been successfully
targeted by currently marketed drugs, such as the previously
discussed antifolate targets DHFR (E=1.02610
2134), thymidylate
synthase (E=2.54610
275), and dihydrofolate synthase
(E=1.35610
270). This retrospective result illustrates the potential
of such additional information in enriching for targets and drug
chemistry that have been proven accessible. Other targets and
pathways have not yet yielded successful drugs but are under
investigation in MRSA or other pathogens, such as the shikimate
pathway [49] in aromatic amino acid biosynthesis and the
histidine biosynthesis pathway [50].
The combination of the essentiality data with the drug space
mapping emphasizes the challenges to drug discovery against
MRSA. Thus, while species-specific antifolates do exist, many
antifolates such as methotrexate used in cancer therapy cause
severe toxicity [43]. To avoid such toxicity, 14 of the 39 essential
MRSA reactions that are also present in humans can be excluded
from further consideration as drug targets in MRSA.
A compilation of all of the metabolic network maps generated in
this study is available at http://sea.docking.org/metabolism.
These include interactive versions of the human effect-space maps
shown in Figure 3, one for each of the 246 MDDR drug classes
analyzed in this work, and 385 species-specific maps such as that
shown in Figure 5. The species-specific maps were generated
Table 2. Links between selected drug classes and top ranked metabolic reactions.
Rank Thymidylate Synthetase (TS) Inhibitor E-value
1 Dihydrofolate reductase (DHFR) 1.96E-123
2 Methyltetrahydrofolate-corrinoid-iron-sulfur protein methyltransferase 3.58E-102
3 Methionyl-tRNA formyltransferase 1.97E-99
4 Methylenetetrahydrofolate reductase 2.67E-86
5 Thymidylate synthase (TS) 2.54E-75
6 Formate-tetrahydrofolate ligase 1.44E-74
7 Dihydrofolate synthetase 1.35E-70
8 Aminomethyltransferase 7.13E-63
9 5-methyltetrahydrofolate-homocysteine S-methyltransferase 2.80E-62
10 Phosphoribosylaminoimidazolecarboxamide (AICAR) formyltransferase 1.50E-60
11 Phosphoribosylglycinamide formyltransferase (GART) 1.50E-60
Rank Dihydrofolate Reductase (DHFR) Inhibitor E-value
1 Dihydrofolate reductase (DHFR) 1.46E-82
2 Methyltetrahydrofolate-corrinoid-iron-sulfur protein methyltransferase 2.84E-75
3 Methylenetetrahydrofolate reductase 6.01E-73
4 Methionyl-tRNA formyltransferase 7.00E-66
5 Aminomethyltransferase 6.90E-55
6 Formate-tetrahydrofolate ligase 6.15E-49
7 Thymidylate synthase (TS) 1.91E-48
8 5-methyltetrahydrofolate-homocysteine S-methyltransferase 2.60E-45
9 3-methyl-2-oxobutanoate hydroxymethyltransferase 2.68E-44
10 Glycine decarboxylase 2.68E-44
11 Glycine hydroxymethyltransferase (SHMT) 2.68E-44
12 Dihydrofolate synthetase 9.65E-42
13 Phosphoribosylaminoimidazolecarboxamide (AICAR) formyltransferase 2.21E-39
14 Phosphoribosylglycinamide formyltransferase (GART) 2.21E-39
Rank Nucleoside Reverse Transcriptase Inhibitor (NRTI) E-value
1 Thymidylate kinase 7.48E-28
2 Thymidine kinase 3.48E-26
3 Deoxythymidine diphosphate kinase 1.54E-24
4 Ribonucleoside-triphosphate reductase 2.88E-14
5 Deoxyuridine triphosphate pyrophosphatase 5.60E-12
6 Deoxyuridine kinase 1.14E-11
7 Deoxyuridine diphosphate kinase 1.45E-11
8 Thymidylate synthase (TS) 5.68E-11
doi:10.1371/journal.pcbi.1000474.t002
Drug Discovery in Small Molecule Metabolism
PLoS Computational Biology | www.ploscompbiol.org 7 August 2009 | Volume 5 | Issue 8 | e1000474from the BioCyc database public collection, a compendium of 385
model organisms and pathogens whose genomes have been
sequenced and their metabolomes deciphered. Of these, 65 have
been designated as Priority Pathogens by the National Institute of
Allergy and Infectious Diseases (NIAID) and include Bacillus
anthracis, Brucella melitensis, Cryptosporidium parvum, Salmonella, SARS,
Toxoplasma gondii, Vibrio cholerae, and Yersinia pestis [51]. Browse and
similarity search tools are also provided, allowing exploration of
the metabolic reaction sets and current drug classes used in this
work, as well as comparison to user-defined custom ligand sets.
These interactive tools enable facile exploration between the vast
biological data on potential metabolic drug targets in these
organisms and the drug chemistry currently available to prosecute
those targets.
Discussion
A key product of this study is the construction of drug-
metabolite correspondence maps that provide both a global view
and a more contextual picture of predicted drug action in human
metabolism than has been previously available. Several aspects of
these maps deserve particular emphasis. First, despite the
differences in physiochemical properties of most drugs and small
molecule metabolites, numerous links arise between drugs and
metabolism. Viewed in the context of metabolic networks, the
pharmacological relationships predicted by these links can be
readily interpreted in a way that is biologically sensible. Moreover,
as shown by both the drug effect space maps and species-specific
maps, our retrospective analyses confirm that biologically and
Figure 4. Selected links between MDDR drug classes and human folate and pyrimidine metabolism.
doi:10.1371/journal.pcbi.1000474.g004
Table 3. Links between selected metabolic reactions and top
ranked drug classes.
Rank Thymidylate Synthetase (TS) Reaction E-value
1 Thymidylate synthase inhibitor (TS) 2.54E-75
2 Glycinamide ribonucleotide formyltransferase inhibitor
(GART)
4.76E-73
3 Thymidine kinase inhibitor (TK) 1.18E-62
4 Dihydrofolate reductase inhibitor (DHFR) 1.91E-48
5 Folylpolyglutamate synthetase inhibitor 2.27E-31
6 Nucleoside reverse transcriptase inhibitor (NRTI) 5.68E-11
Rank Dihydrofolate Reductase (DHFR) Reaction E-value
1 Glycinamide Ribonucleotide Formyltransferase
Inhibitor
1.02E-134
2 Thymidylate Synthetase Inhibitor 1.96E-123
3 Dihydrofolate Reductase Inhibitor 1.46E-82
4 Folylpolyglutamate Synthetase Inhibitor 3.15E-62
doi:10.1371/journal.pcbi.1000474.t003
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capturing known polypharmacology and revealing the relevant
chemotypes previously explored in drug development. The
metabolome-wide exploratory tools provided with these map sets
also enable a new way to interrogate the links between drugs and
metabolism that will likely be useful for prediction of new targets
and to indicate routes of drug metabolism and toxicity. Further, by
integrating biological information such as essentiality and synthetic
lethal analyses with the metabolic context, our approach allows
users to focus evaluation of potential targets around specific types
of data simply by painting the results on to metabolic maps.
With respect to the coverage of drug links across small molecule
metabolism that this study provides, we note that the SEA method
relies solely upon the chemical similarity of ligands to establish
links between drug sets and reaction sets. Based on these links, and
the biologically sensible connections shown in the results, we infer
that a particular drug class may act on a certain target. However,
drugs may also act against an enzyme active site without
resembling the endogenous substrate, or by allosteric regulation
at an entirely different site. The SEA method, as applied here to
the substrates and products of metabolic reactions, does not
capture these additional drug-target links. Other viable strategies
are available for targeting metabolic enzyme active sites that use
principles unrelated to the ligand-drug similarities that are the
focus of our approach [52–55]. For instance, Tondi et al. designed
novel inhibitors of thymidylate synthase that complemented the
three dimensional structure of the active site. Five high-scoring
compounds selected for testing were dissimilar to the substrate but
bound competitively with it [55]. While many classical kinase
inhibitors interact directly with the ATP binding site, imatinib
(tradename Gleevec) represents a new generation of allosteric
protein kinase inhibitors that alter the kinase conformation to
prevent ATP binding. Other allosteric kinase inhibitors prevent
the protein substrate from loading [52].
While a quantitative determination of the proportion of drug-
target links that cannot be accessed by our approach is beyond the
scope of this study, we can provide a rough estimate for the
frequency of such cases based on the results reported in Table 1.
Of the 62 known enzyme targets in MetaCyc, 42 (68%) the
substrate/product metabolite sets show significant chemical
similarity to at least one MDDR drug set, establishing a reasonable
first pass estimate for the percentage of current enzyme targets
accessible to this approach. Furthermore, 40% (2,044 of 5,056) of
all MetaCyc reaction sets linked at E=1.0610
210 or better to
MDDR, with each reaction linking to an average of just 2.8
MDDR drug sets. These results indicate broad and specific
coverage of metabolism, and suggest that numerous additional
enzyme targets may be accessible by the method presented here.
Figure 5. Effect-space map showing chemical similarity between drugs and metabolites in MRSA. Canonical pathway representation of
methicillin-resistant Staphylococcus aureus (MRSA) [12] small molecule metabolism colored by expectation value of the best hit against MDDR.
Reactions that are also present in humans have been faded. Layout based upon the Cytoscape 2.5 y-files hierarchical layout. Edge lengths are not
significant. For ease of viewing, reactions are not labeled but can be identified in the interactive versions of the maps available at the online resource.
doi:10.1371/journal.pcbi.1000474.g005
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Using the SEA method, we have shown that comparison between
ligand sets representing MDDR drug classes and ligand sets
representing the substrates and products of metabolic reactions yields
statisticallysignificantlinksbetweenknowndrugsandenzymetargets.
Because the method is based on chemical similarity and requires only
information from these molecule sets rather than the sequence,
structure or physiochemistry of the targets, this ligand-based
approach is independent from, and complementary to, protein
structure and sequence based methods. Our results also suggest the
potential of this method for predicting previously unknown
interactions between drug classes and metabolic targets, recovering
routes of metabolism and toxicity in humans, and identifying
p o t e n t i a ld r u gt a r g e t s( a sw e l la sc h a l l e n g e sf o rt a r g e td i s c o v e r y )i n
emerging pathogens. Thus, by mapping the chemical diversity of
drugs to small molecule metabolism using ligand topology, this work
establishes a computational framework for ligand-based prediction of
drug class action, metabolism, and toxicity.
Methods
Compound sets. All compounds, both drugs and
metabolites, are represented using Daylight SMILES strings
[29]. Sets comprised of isomers with unique compound names
were retained, even though stereochemistry was later removed as
part of the molecule fingerprinting process.
Ligand sets. Reaction sets were extracted from the 8.15.2007
release of MetaCyc based upon the substrates and products
annotated to each reaction. Two filters were applied. First, the ten
most common metabolites based on the number of occurrences in
the MetaCyc metabolic network were removed: water, ATP, ADP,
NAD, pyrophosphate, NADH, carbon dioxide, AMP, glutamate,
and pyruvate. Second, each reaction set was required to include at
least two unique compounds, as indicated by a MetaCyc or a
MDDR unique compound id.
Drug sets. Drug sets were extracted from the MDDR, a
compilation of about 169,000 drug-like ligands in 688 activity
classes, each targeting a specific enzyme (designated by the
Enzyme Commission (E.C.) number). The subset of this database
for which mappings between enzymes and the MDDR drug
classes were available was used. These mappings were based on a
previous study that maps E.C. numbers, GPCRs, ion channels and
nuclear receptors to MDDR activity classes [32]. Only sets
containing five or more ligands were used. Salts and fragments
were removed, ligand protonation was normalized and duplicate
molecules were removed. Of the 688 targets in the MDDR, 97
were excluded as having too few ligands (,5), and another 345
targets were excluded because their definitions did not describe a
molecular target, e.g., drugs associated only with an annotation
such as ‘‘Anticancer’’ were not used. The remaining 246 enzyme
targets were together associated with a total of 65,241 unique
ligands, with a median and mean of 124 and 289 drug ligands per
target. For further details, see Keiser et al. [6].
Set comparisons. All pairs of ligands between any two sets
were compared using a pair-wise similarity metric, which consists of a
descriptor and a similarity criterion. For the similarity descriptor,
standard two-dimensional topological fingerprints were computed
using the Scitegic ECFP4 fingerprint [56]. The similarity criterion
Figure 6. Essential and synthetic lethal map of MRSA metabolism. Canonical pathway representation of methicillin-resistant Staphylococcus
aureus (MRSA) small molecule metabolism colored by essentiality and synthetic lethality of reactions. Key: black=essential reaction; other
colors=synthetic lethal reaction pairs; node size=similarity to top MDDR hit (bigger is more drug-like); diamond shape=MDDR drug target; faded
border=human reaction.
doi:10.1371/journal.pcbi.1000474.g006
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comparisons, all pair-wise Tcs between elements across sets were
calculated, and those scoring above a threshold were summed, giving
a raw score relating the two sets. The Tanimoto coefficient threshold
of 0.32 was determined according to a previously published method
based upon fit to an extreme value distribution [6]. A model for
random similarity similar to that used by BLAST [58] was used to
generate expectation values (E) which are used to describe the
strengths of relationships discovered using this protocol [6]. All scores
reported here are based upon the background distribution and cutoff
scores generated using the drug sets extracted from the MDDR
c o l l e c t i o n .F o rf u r t h e rd e t a i l s ,s e eK e i s e re ta l .[ 6 ] .N e t w o r k
visualization was performed in Cytoscape 2.6.2 [59] using the c-
files hierarchical layout algorithm.
MRSA essentiality and synthetic lethal analysis. Essen-
tiality and synthetic lethal data generated as described earlier [48].
Briefly, the metabolic network was reconstructed from the genome to
include all reactions that have an active flux The essentiality of a given
enzyme was then assessed by the effect of the removal of that enzyme
on biomass production. Similarly, synthetic lethal pairs can be
identified by systematic pairwise deletion of enzymes and
recalculation of biomass production in an ideally rich medium.
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